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A nationwide antimicrobial resistance surveillance has been
conducted since 1997 in Korea. In this study, susceptibility
test data generated in 2004 by KONSAR group hospitals were
analyzed and compared to those at a commercial laboratory.
In hospitals, the rank orders of organisms in 2004 were
identical to those in 2003. The most prevalent species was
Staphylococcus aureus (20.2%) in hospitals, but Escherichia
coli (29.7%) in the commercial laboratory. The proportions of
Enterococcus faecium to all isolates of Enterococcus faecalis
plus E. faecium were 47.2% in hospitals and 24.9% in the
commercial laboratory. The mean resistance rates of significant
antimicrobial-organism combinations in hospitals were: oxacil-
lin-resistant S. aureus (68%), oxacillin-resistant (penicillin-
nonsusceptible) Streptococcus pneumoniae (68%), vanco-
mycin-resistant E. faecium (25%), cefotaxime-resistant E. coli
(14%), ceftazidime- and cefoxitin-resistant Klebsiella pneu-
moniae (34% and 32%, respectively), and imipenem-resistant
Acinetobacter spp. and Pseudomonas aeruginosa (17% and
24%, respectively). In conclusion, oxacillin-resistant staphylo-
cocci, expanded-spectrum cephalosporin-resistant K. pneu-
moniae, and imipenem-resistant Acinetobacter spp. and P.
aeruginosa were prevalent in 2004. Increasing trends were
observed for vancomycin-resistant E. faecium, cefoxitin-
resistant E. coli and K. pneumoniae, and imipenem-resistant
Acinetobacter spp. and P. aeruginosa. Certain antimicrobial-
organism combinations were also prevalent among the com-
mercial laboratory-tested strains.
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INTRODUCTION
Alarming rises in the prevalence of certain
pathogenic bacteria resistant to some antimicro-
bial agents has been noted worldwide. Antimicro-
bial selective pressures, which are the primary
determining factors of the prevalence of resistant
bacteria, differ significantly depending on the
region and time. Therefore, monitoring resistance
is necessary for empirical selection of the most
appropriate antimicrobial agents to treat infected
patients. Monitoring temporal trends of resistance
is considered most beneficial for the detection of
subtle changes in resistance.
1
Antimicrobial resistance surveillance is also
necessary to assess the extent of problems and
determine the need for intervention.2 Alexander,
PROTEKT, SENTRY, and other programs3,4 are
good examples conducted internationally by col-
lecting strains and testing by a reference labora-
tory. For example it was believed that the
Alexander project had provided a resource for
measuring trends in the susceptibility patterns of
respiratory pathogens at the national, regional
and global levels.4 These type programs can
provide the most accurate information. However,
they are very costly. Analysis of routine suscep-
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tibility test data at hospitals has inherent inac-
curacies due to differences in methodology and
interpretation, but does not require many addi-
tional resources.3,5
The KONSAR program in Korea was initiated
in 1997,6 based on a World Health Organization
recommendation. Two surveillance methods have
been used, which include the analysis of hospital-
tested data, and the testing of collected strains by
the coordinating laboratory. Analysis of test data
in 20037 revealed a further increase of vanco-
mycin-resistant Enterococcus faecium, fluoro-
quinolone-resistant Klebsiella pneumoniae, and
imipenem-resistant Acinetobacter spp. The pre-
vious second program revealed wide dissemina-
tion of metallo- -lactamase (MBL)-producingβ
Acinetobacter spp. and Pseudomonas spp.,8 and
plasmid-mediated CMY-2 and DHA-1 allele-
positive Escherichia coli and K. pneumoniae.9
Currently, more problematic antimicrobial
agent-organism combinations worldwide include
methicillin-resistant Staphylococcus, vancomycin-
resistant E. faecium, expanded-spectrum cephalo-
sporin-resistant K. pneumoniae,10 multidrug resis-
tant (MDR) Acinetobacter spp.11 and imipenem-
resistant Pseudomonas aeruginosa.12
The resistance rates of nosocomially-acquired
bacteria are generally higher than those of
community-acquired ones, necessitating differen-
tiation of these two groups in the analysis. Yet, it
is sometimes difficult to separate them satisfac-
torily. In the previous KONSAR program, data
were collected from hospitals only, but in 2003,
data were also collected from a commercial
laboratory, which tested a large number of
specimens which were submitted mostly from
primary-care clinics in many parts of Korea.7
In the analysis of resistance data, NCCLS13
recommends inclusion of the first isolate of a
given species per patient per analysis period (e.g.,
year), irrespective of the antimicrobial suscep-
tibility profile or other phenotypic characteristics.
When multiple isolates of nosocomial pathogens
from a patient are included, resistance rates be-
come significantly higher, but elimination of du-
plicate isolates may result in the underestimation
of resistance rates and mask trends in emerging
resistance.
5
In this study susceptibility test data generated
by the KONSAR group hospitals were analyzed,
and the resistance rates at hospitals were com-
pared to those at a commercial laboratory. In
addition, the effects of excluding duplicate isolates
of some selected species on resistance rates were
analyzed using test data from the coordinating
laboratory.
MATERIALS AND METHODS
Routine susceptibility test data on common
aerobic bacteria isolated in 2004 were collected
from 44 KONSAR group hospitals located both in
large cities and in small provincial cities through-
out Korea. Data were also obtained from one
commercial laboratory, which tested specimens
received mostly from primary clinics in many
parts of the country. The data from eight hospitals
were excluded from the analysis due to poor per-
formance versus the WHO/CDC quality control
program. Data were also excluded from the an-
alysis when the numbers of isolates in a hospital
were less than 10 for non-typhoidal Salmonella, or
less than 20 for other species.
Three hospital groups, which were determined
based on the location and bed capacity at the time
of initiation of the program ( 1000 beds
countrywide, < 1000 beds in Seoul, and < 1000
beds in non-Seoul), were used to compare mean
resistance rates, despite changes in bed capacity at
some hospitals.
As in the previous study, the mean resistance
rates in each hospital groups were calculated
from the resistance rates at each hospital to
minimize the influence of a large numbers of
isolates at some hospitals.3,14 The data from the
commercial laboratory were analyzed separately.
Resistance rates, which did not include inter-
mediate susceptibility, were calculated from all
isolates, including duplicate ones. The effect of
excluding duplicate isolates on the resistance
rates was analyzed for some antimicrobial-
species combinations using the WHONET 5
program.
15
Statistical significance of resistance
trend was not determined as it was the common
practice in the large scale continuous surveillance
program.
4,16
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RESULTS
Rank order of isolates and methods of suscepti-
bility testing
The number of isolates at hospitals in 2004
increased slightly compared to those in 2003, but
the rank order remained the same in all 13
organisms (Table 1). The most prevalent species in
hospitals was Staphylococcus aureus (20.2%),
however it was E. coli (29.7%) at the commercial
laboratory. The proportions of E. faecium to all
isolates of E. faecalis plus E. faecium were 47.2% in
hospitals and 24.9% at the commercial laboratory.
The responses to our questionnaire showed that
the susceptibility test methods used for E. coli and
S. aureus were the NCCLS disk diffusion method
by 10 and 13 hospitals, the broth microdilution
method (Vitek [bioMerieux, Marcy l'Etoile,
France] or MicroScan [Dade MicroScan Inc., West
Sacramento, CA, U.S.A.] system) by 21 and 17
hospitals, and a combination of the two by one
and two hospitals, respectively. The fluoroquino-
lone susceptibility of gram-negative bacilli was
mostly tested using ciprofloxacin, but some
hospitals used levofloxacin instead. Kinds of
antimicrobial agents used to test the susceptibility
of E. coli and S. aureus were similar to those used
in 2003 (data not shown).
Resistance rates of hospital isolates
The present surveillance showed that the mean
oxacillin resistance rates of S. aureus and
coagulase-negative staphylococci (CNS) in hos-
pitals were 68% and 73%, respectively (Table 2).
The resistance rate of S. aureus was much higher
than that of CNS to fluoroquinolone (60% vs.
35%), but lower to cotrimoxazole (20% vs. 35%).
Of Streptococcus pneumoniae tested, 68% were
oxacillin-screening test positive, suggesting peni-
cillin nonsusceptibility. The ampicillin resistance
rate of E. faecalis was 2% in this study. Ampicillin
and vancomycin resistance rates of E. faecium were
90% and 25%, respectively.
The resistance rates of E. coli to cefotaxime and
K. pneumoniae to ceftazidime were 14% and 34%,
respectively (Table 3). The resistance rates of E.
Table 1. Number, Proportion, and Rank Order of Isolates Tested in 2004
Organism
Hospitals Commercial Lab.*
No. (%) of isolates Rank No. (%) of isolates Rank
Escherichia coli 41,925 (17.7) 2 6,723 (29.7) 1
Klebsiella pneumoniae 25,320 (10.7) 5 2,513 (11.1) 4
Enterobacter cloacae 7,854 (3.3) 9 703 (3.1) 9
Serratia marcescens 5,743 (2.4) 10 1,068 (4.7) 8
Nontyphoidal Salmonella 545 (0.2) 13 164 (0.7) 12
Acinetobacter spp. 15,338 (6.5) 6 1,331 (5.9) 7
Pseudomonas aeruginosa 31,544 (13.3) 3 2,984 (13.2) 2
Haemophilus influenzae 954 (0.4) 12 138 (0.6) 13
Staphylococcus aureus 47,823 (20.2) 1 2,875 (12.7) 3
Coagulase-negative staphylococci 28,809 (12.1) 4 1,771 (7.8) 5
Enterococcus faecalis 14,795 (6.2) 7 1,509 (6.6) 6
E. faecium 13,211 (5.6) 8 500 (2.2) 10
Streptococcus pneumoniae 3,297 (1.4) 11 339 (1.5) 11
Total 237,158 (100) 22,618 (100)
*Majority of the specimens were collected from primary care clinics in outside of Seoul.
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coli and K. pneumoniae to cefoxitin were 8% and
32%, respectively (Table 3). The lowest resistance
rates to cephalosporins shown by Enterobacter
cloacae and Serratia marcescens were to cefepime,
8% and 17%, respectively. Imipenem-resistant E.
coli, K. pneumoniae, E. cloacae and S. marcescens
isolates existed, although the rates were very low
(Table 3).
The resistance rates of Acinetobacter spp. were
lower to imipenem (17%) and cefoperazone-
sulbactam (19%) than to other antimicrobial
agents, and those of P. aeruginosa were lower to
ceftazidime (19%), and meropenem (20%), but
slightly higher to imipenem (24%).
The resistance rates to gentamicin and tobra-
mycin in this study were relatively high: in E. coli
24% and 20%, respectively, and in K. pneumoniae
26% and 36%, respectively. Amikacin resistance
rates were 10% to 46%, except for E. coli (Table 3).
E. cloacae was the species with the lowest
resistance rate to fluoroquinolone, 11%, while
Acinetobacter spp. was the species with the highest
resistance rate of 56%.
The resistance rates of nontyphoidal Salmonella
to ampicillin, cotrimoxazole, and fluoroquinolone
were 44%, 7% and 0.7%, respectively (data not
shown). Among the Haemophilus influenzae isolates
47% were resistant to ampicillin and 51% pro-
duced -lactamase.β
Resistance rates of commercial laboratory-tested
isolates
The resistance rates of S. aureus to oxacillin
(58%) and gentamicin (54%), and those of E.
faecium to ampicillin (78%), fluoroquinolone (69%),
and vancomycin (11%) at the commercial
laboratory were lower than those in hospitals
(Table 2). A comparison of the resistance rates of
the commercial laboratory-tested gram-negative
bacilli to those of hospital isolates showed that the
cefotaxime resistance rates of E. coli were 12% and
14%, respectively, and cefoxitin resistance rates of
K. pneumoniae were both 32%. However, cefotaxime,
ticarcillin-clavulanic acid, and amikacin resistance
rates of E. cloacae and S. marcescens were much
Table 2. Antimicrobial Resistant Rates of Gram-Positive Cocci Tested at Hospitals and at a Commercial Laboratory
Antimicrobial agents
Percent of isolates resistant (No. of isolates tested)
S. aureus CNS S. pneumoniae E. faecalis E. faecium
Hospitals
(47,823)
C-Lab
(2,875)
Hospitals
(28,809)
C-Lab
(1,771)
Hospitals
(3,297)
C-Lab
(339)
Hospitals
(14,795)
C-Lab
(1,509)
Hospitals
(13,211)
C-Lab
(500)
Oxacillin 68 58 73 72 68* 40 NT NT NT NT
Penicillin/ampicillin 96 97 92 91 NT NT 2 2 90 78
Clindamycin 37 42 37 21 NT NT NT NT NT NT
Erythromycin 46 57 58 47 62 77 NT NT NT NT
Cotrimoxazole 20 20 35 22 NT NT NT NT NT NT
Tetracycline 32 47 34 39 NT NT 80 87 13 21
Gentamicin 65 54 52 26 NT NT NT NT NT NT
Fluoroquinolone§ 60 NT 35 NT NT NT 34 27 91 69
Teicoplanin 0 0 0.5 0 NT NT 1 0 20 8
Vancomycin 0 0 0 0 NT NT 1 0 25 11
* Indicates proportion of penicillin-nonsusceptible isolates.
Resistance determined by a broth microdilution test.
Resistance rates to penicillin for staphylococci and to ampicillin for enterococci.
§
Majority of the laboratories used ciprofloxacin.
CNS, coagulase-negative staphylococci; C-Lab, commercial laboratory; NT, not tested.
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lower. The imipenem and meropenem resistance
rates of P. aeruginosa, 13% and 15%, respectively,
were only slightly lower than those found in
hospitals, but resistance rates of Acinetobacter spp.,
6% and 11%, respectively, were much lower
(Table 3).
The E. coli isolates tested by the commercial
laboratory, and those by the hospitals, showed
similar fluoroquinolone resistance rates, 33% and
32%, respectively. It is interesting to note that the
commercial laboratory-tested Acinetobacter spp.
and P. aeruginosa showed higher fluoroquinolone
resistance rates than hospital isolates (Table 3).
Trends of significant resistance
The prevalence of oxacillin-resistant S. aureus
and penicillin-nonsusceptible S. pneumoniae remained
similar, but a further increase of ampicillin- and
vancomycin-resistant E. faecium was observed
Table 3. Antimicrobial Resistance Rates of Gram-Negative Bacilli Tested at Hospitals and at a Commercial Laboratory
Antim icrobial
agents
Percent of isolates resistant (No. of isolates tested)
E. coli K. pneumoniae E. cloacae S. marcescens Acinetobacter P. aeruginosa
Hosp ita ls
(40,651 )
C -Lab
(6 ,723)
Hosp ita ls
(25,320)
C -L ab
(2,513 )
H osp ita ls
(7 ,854)
C -Lab
(703)
H ospitals
(5,743)
C -Lab
(1 ,068 )
H ospitals
(15 ,338)
C -Lab
(1 ,331)
Hosp ita ls
(31,544 )
C -L ab
(2,984 )
Ampicillin 65 70 - - - - - - - - - -
Ampicillin-sulbactam 36 NT 42 NT - - - - 40 NT - -
Cephalothin 32 27 46 48 - - - - - - - -
Cefotaxime 14 12 28 41 35 21 29 13 62 NT 57 NT
Ceftazidime 10 11 34 44 35 27 23 8 57 60 19 21
Aztreonam 11 NT 30 NT 33 NT 24 NT 72 79 26 22
Cefepime 11 NT 19 NT 8 NT 17 NT 49 42 23 20
Cefoperazone-sulbactam 6 NT 13 NT 8 NT 28 NT 19 NT 21 NT
Cefoxitin 8 7 32 32 NT NT NT NT NT NT NT NT
Cefotetan 6 NT 18 NT NT NT NT NT NT NT NT NT
Piperacillin 60 NT 45 NT 28 NT 42 NT 55 65 36 30
Piperacillin-tazobactam 5 1 18 5 23 5 22 2 36 15 25 17
Ticarcillin-clavulanate 10 13 30 38 37 22 32 29 29 37 38 45
Imipenem 0.1 0 0.7 0 0.5 0 3 0 17 6 24 13
Meropenem 0 NT 0.1 NT 0.3 NT 9 NT 22 11 20 15
Amikacin 3 4 22 30 10 6 18 13 46 28 24 35
Gentamicin 24 29 26 35 23 26 39 43 59 62 37 45
Tobramycin 20 15 36 45 32 32 51 57 60 60 34 44
Fluoroquinolone* 32 33 31 41 11 9 18 16 56 68 38 48
Cotrimoxazole 35 15 36 32 26 30 21 29 57 54 95 100
Tetracycline 54 NT 16 NT 21 NT 69 NT 65 NT 95 NT
-Not applicable because of natural resistance.
*Majority of the laboratories used ciprofloxacin for testing.
NT, not tested.
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(Fig. 1). The resistance rates of K. pneumoniae to
ceftazidime, cefoxitin, fluoroquinolone and
amikacin also increased (Fig. 2).
Acinetobacter spp. showed a slight downward
trend in resistance to fluoroquinolone, amikacin,
and ceftazidime, but a steady upward trend in
resistance to imipenem (Fig. 3). In the comparison
of the resistance trends of the isolates in 2003 and
2004, the resistance rates to all three aminogly-
cosides, and to some -lactams, decreased slightly,β
but the resistance to imipenem and cefoperazone-
sulbactam was slightly increased (Fig. 4).
In the comparison of resistance rates by hospital
groups, isolates of vancomycin-resistant E. faecium,
fluoroquinolone-resitant E. coli, cefoxitin-resistant
K. pneumoniae, imipenem-resistant P. aeruginosa
and Acinetobacter spp. were relatively more pre-
valent at the large hospital group than at the
medium-size hospital group (Fig. 5). At the com-
mercial laboratory, the rates of vancomycin-
resistant E. faecium, imipenem-resistant P. aeruginosa
and Acinetobacter spp. were lower, but the rate of
Fig. 2. Temporal changes of ceftazidime, cefoxitin, fluoro-
quinolone and amikacin resistance in K. pneumoniae. All
of these resistances increased in 2004. CAZ, ceftazidime;
FOX, cefoxitin; FQN, fluoroquinolone; AMK, amikacin;
R, resistant.
Fig. 1. Temporal changes of oxacillin-resistant S. aureus,
ampicillin- and vancomycin-resistant E. faecium and peni-
cillin-nonsusceptible S. pneumoniae. A continued increase
of vancomycin-resistant E. faecium was observed. OXA,
oxacillin; AMP, ampicillin; PEN, penicillin G; VAN, van-
comycin; SAU, Staphylococcus aureus; EFM, Enterococcus
faecium; SPN, Streptococcus pneumoniae; NS, nonsuscep-
tible;. R, resistant.
Fig. 3. Temporal changes of fluoroquinolone, amikacin,
ceftazidime and imipenem resistance in Acinetobacter
spp. A continued increase of imipenem resistance was
observed. FQN, fluoroquinolone; AMK, amikacin; CAZ,
ceftazidime; IPM, imipenem; R, resistant.
Fig. 4. Comparison of antimicrobial resistance rates of
Acinetobacter spp. isolated in 2003 and in 2004. Resis-
tance rates to carbapenem and cefoperazone-sulbactam
remained relatively low, but those to other antimicrobial
agents were very high. IPM, imipenem; MER, mero-
penem; C/S, cefoperazone-sulbactam; P/T, piperacillin-
sulbactam; A/S, ampicillin-sulbactam; FEP, cefepime;
PIP, piperacillin; CAZ, ceftazidime; CTX, cefotaxime;
AZT, aztreonam; AMK, amikacin; GEN, gentamicin;
TOB, tobramycin; CIP, ciprofloxacin; COT, cotrimoxa-
zole; TET, tetracycline.
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fluoroquinolone-resistant E. coli was similar.
Resistance rates excluding duplicate isolates
Coordinating laboratory data showed that the
resistance rates including all isolates were more
than 5% higher compared to those including only
the first isolate from a patient in oxacillin-resistant
S. aureus, vancomycin-resistant E. faecium fluoro-
quinolone-resistant E. coli, ceftazidime-resistant K.
pneumoniae, piperacillin- and imipenem-resistant
P. aeruginosa (Fig. 6). The data from the coor-
dinating laboratory were used to determine the
time (day) between the first isolation of an
imipenem-susceptible strain and the subsequent
isolation of an imipenem-resistant strain of P.
aeruginosa from same patients. The first resistant
strain was detected within 4 weeks in 58 of 78
(74%) patients (Fig. 7). This suggested that, even
in the monthly analysis of resistance rates, in-
cluding the susceptibility of only the first isolate
may result in the underestimation of the preva-
lence of some other resistances.
DISCUSSION
A comparison of total number of isolates tested
in 2004 vs. 2003 showed a slight increase at
hospitals, whereas there had been a significant
decrease at the commercial laboratory (Table 1).
The rank order remained the same for all 13
organisms in hospitals, but at the commercial
laboratory, K. pneumoniae moved from the fifth to
the fourth most prevalent, and coagulase-negative
staphylococci dropped from the fourth to the fifth
most prevalent.
7
Fig. 5. Prevalence of problem antimicrobial-organism
combinations in different hospital groups and at the
commercial laboratory. Vancomycin-resistant E. faecium,
and imipenem-resistant P. aeruginosa and Acinetobacter
spp. were more prevalent among strain isolated from
large hospitals than those tested at a commercial labora-
tory. S-Med, Seoul-medium; N-Med, non-Seoul-medium;
Comm Lab, commercial laboratory; VAN, vancomycin;
FQN, fluoroquinolone; FOX, cefoxitin; IMP, imipenem;
EFM, Enterococcus faecium; ECO, Escherichia coli; KPN,
Klebsiella pneumoniae; PAE, Pseudomonas aeruginosa; ABA,
Acinetobacter baumannii; R, resistant.
Fig. 6. Comparison of resistance rates by including du-
plicate isolates and by including only the first isolate
from a patient per year. The difference was relatively
greater in piperacillin- and imipenem-resistant P. aeruginosa,
and oxacillin-resistant S. aureus. OXA, oxacillin; VAN,
vancomycin; FQN, fluoroquinolone; CAZ, ceftazidime;
CTX, cefotaxime; PIP, piperacillin; IPM, imipenem; SAU,
Staphylococcus aureus; EFM, Enterococcus faecium; ECO,
Escherichia coli; KPN, Klebsiella pneumoniae; SMA, Serratia
marcescens, PAE, Pseudomonas aeruginosa; R., resistant.
Fig. 7. The time (day) between the first isolation of an
imipenem-susceptible strain and the subsequent isola-
tion of an imipenem-resistant strain of P. aeruginosa. The
first resistant strain was detected within 4 weeks in 58
of 78 (74%) patients.
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Kinds of antimicrobial agents used to test
susceptibility of E. coli and S. aureus did not
change significantly compared to those in 2003.
With the increasing prevalence of CTX-M type
extended-spectrum -lactamase (ESBL) in Korea,β
testing the susceptibility of E. coli, K. pneumoniae
and Proteus mirabilis to at least ceftazidime and
cefotaxime became necessary for optimal
detection of the enzymes,17 but not all hospitals
tested susceptibility to both of these antimicrobial
agents.
The mean oxacillin resistance rates of S. aureus
and coagulase-negative staphylococci (CNS) in
hospitals were 68% and 73%, respectively (Table
2). Oxacillin-resistant S. aureus is now highly
prevalent, not only in Japan,18 but in other
countries as well. Over 40% of S. aureus isolates
in Greece, Italy, and United Kingdom were
oxacillin-resistant, according to a surveillance
study in 1999-2002.19 The penicillin G breakpoint
for Streptococcus pneumoniae is for the treatment of
meningitis. A high penicillin G non-susceptible
rate of pneumococci by oxacillin-disk screening
test (68%) in this study suggests that empirical
selection of penicillin G, without susceptibility
testing, may result in a high rate of clinical failure
in the treatment of meningitis. Penicillin-non-
susceptible pneumococci are very prevalent in
some other Asian countries, as well,20 and in-
creased penicillin resistance was also reported in
the United States in the 1990s.21
The proportion of ampicillin-resistant E. faecalis
was 2% in this study. Ampicillin-resistant E.
faecalis was considered to be a misidentification of
E. faecium in surveillance of the United Kingdom.22
A thorough review of other unexpected anti-
biograms, such as < 100% vancomycin suscep-
tibility for S. aureus, < 100% imipenem suscepti-
bility for Escherichia coli, and > 0% ampicillin
susceptibility for K. pneumoniae, was also recom-
mended to improve the quality of surveillance
data.23 The vancomycin resistance rate of E.
faecium was 25%. Difficulty in the control of
vancomycin-resistant enterococci was shown by a
high prevalence at a Chicago hospital,
24
where the
proportion of vancomycin-resistant E. faecium
isolates increased from 28.9% to 72.4%, between
1993 and 2002.
The resistance rates of E. coli to cefotaxime and
K. pneumoniae to ceftazidime were 14% and 34%,
respectively (Table 3). E. coli and K. pneumoniae
often acquire ESBL genes. In Korea, TEM-, SHV-,
CTX-M-type ESBLs were reported.25-27 An analysis
of K. pneumoniae strains collected between 1998
and 2002 from Asian countries28 showed that
ESBL-producing isolates were particularly pre-
valent in Singapore (35.6%), China (30.7%), and
the Philippines (21.9%). Increased prevalence of
ESBL-producing E. coli and Klebsiella spp. over
time was also reported in Europe.29
The cefoxitin resistance rate of K. pneumoniae
was 32% (Table 3). A majority of the resistant
isolates likely produced plasmid-mediated AmpC
-lactamases. DHA-1 and CMY-2 enzymes wereβ
reported to be the prevalent plasmid-mediated
AmpC enzymes in Korea.9,30,31 Dissemination of E.
coli and K. pneumoniae strains producing plasmid-
mediated AmpC -lactamases has become aβ
worldwide problem,32 since the enzymes confer
resistance not only to cephalosporins and
cephamycins, but also to carbapenems when the
mechanism is combined with porin loss.33
Imipenem-resistant E. coli, K. pneumoniae, E.
cloacae and S. marcescens isolates existed, although
the rates were very low (Table 3). MBL-producing
E. cloacae,34,35 and S. marcescens and Citrobacter
freundii35 were reported in Korea. The resistance
rates of Acinetobacter spp. were lower to imipenem
(17%) and cefoperazone-sulbactam (19%) than to
other antimicrobial agents. Higgins et al.36 re-
ported that in vitro activity of -lactam- -lactaβ β -
mase inhibitor combinations against A. baumannii
are mainly determined by the intrinsic activity of
the inhibitors alone. It was reported that sul-
bactam has a good intrinsic activity against MDR
Acinetobacter strains at concentrations readily
achievable in human serum and may therefore
have some therapeutic implications in the
treatment of infections caused by MDR A.
baumannii infections. Smolyakov et al.37 reported
that ampicillin-sulbactam appeared to be one of
the last effective and safe empirical resorts for the
treatment of MDR A. baumannii bloodstream
infections, but in our present study, the resistance
rate to this combination was not low (40%).
Increasing resistance of P. aeruginosa and
Acinetobacter spp. to carbapenems is the most
serious problem, as it is the only class of -lactamβ
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active against ESBL- and derepressed AmpC
enzyme-producing organisms.38 Various mecha-
nisms are involved in carbapenem resistance.12 In
Korea, VIM-2 and IMP-1 type acquired metallo- -β
lactamases (MBLs) were reported in these organ-
isms.8,39-41 Certain types of OXA enzymes can
hydrolyze carbapenem. Carbapenem-hydrolyzing
OXA-23 enzyme was detected in outbreak strains
of imipenem-resistant A. baumannii, which
involved 36 patients at a university hospital in
2003.42 In Brazilian hospitals, resistance rates of
Acinetobacter spp. to carbapenem have reached
12% or higher.43 Thus, more toxic agents, such as
polymyxin, have been used, and as a conse-
quence, it was found that 5 out of 100 blood
isolates of Acinetobacter spp. were resistant to this
drug.
Increasing amikacin resistance in some species
of gram-negative bacilli (Table 3) suggest that
empirical selection of this aminoglycoside has also
became difficult. Fluoroquinolones are frequently
used, as they are one of the three major broad-
spectrum classes of antimicrobial agents,44 but
56% of Acinetobacter spp. isolates were resistant to
this drug.
Compared to the previous report of ampicillin
and cotrimoxazole resistance rates (both 34%) of
Salmonella enterica serovar Typhymurium DT104,45
the resistance rate to ampicillin was higher, but
the rate to cotrimoxazole was much lower.
Nontyphoidal Salmonella infections are mostly
acquired in communities rather than in hospitals.
Therefore, an increase of ampicillin-resistant
isolates may suggest prevalence of this resistance
in the community. The fluoroquinolone-resistance
rate remained very low, but this low rate may not
be useful to predict clinical efficacy for the
treatment of extra-intestinal Salmonella infections,
because low-level quinolone resistance is clinically
relevant but not detectable by using fluoro-
quinolones. A similar ampicillin resistance rate of
47% and -lactamase production rate of 51% inβ
Haemophilus influenzae isolates in this study
suggests that -lactamase-negative ampicillin-β
resistant (BNAR) H. influenzae remain rare in
Korea, although it has been a prevalent type in
Japan.46
In general, resistant bacteria are more prevalent
among hospital isolates. However the cefotaxime
resistance rate of E. coli (12%) at the commercial
laboratory was similar to that in hospitals (14%),
suggesting a spread of ESBL-producing strains to
the community or to small hospitals. Presence of
imipenem-resistant P. aeruginosa and Acinetobacter
spp. at the commercial laboratory also suggests a
spread of this resistance to small hospitals. The
similar fluoroquinolone resistance rates of E. coli
at the commercial laboratory (33%) and in hos-
pitals (32%) suggest the presence of fluoroquino-
lone-resistant E. coli in the community (Table 3).
In a Taiwanese surveillance study in 2000, fluoro-
quinolone resistance is found among isolates from
both inpatients and outpatients, not only in
medical centers, but also at regional hospitals
throughout the country.47
A further increase of cefoxitin-resistant K.
pneumoniae was observed in this study (Fig. 2). A
previous KONSAR study showed that plasmid-
mediated CMY-2 and DHA-1 AmpC-producing K.
pneumoniae isolates were prevalent in Korea.8 It is
a concern that plasmid-mediated AmpC can
confer resistance to imipenem when combined
with porin loss.
Acinetobacter spp. showed slight decreased
resistance to fluoroquinolone, amikacin, and cefta-
zidime, but a steady upward trend of resistance
to imipenem (Fig. 3). A recent increase in
carbapenem usage probably caused these two
different trends. In the 2003 KONSAR study,8
many isolates of Acinetobacter spp. showed MDR
patterns.
The lower rates of vancomycin resistance in E.
faecium, imipenem resistance in P. aeruginosa and
Acinetobacter spp., but the similar rate of fluoro-
quinolone resistance in E. coli at the commercial
laboratory in this study, may be due to less use
of vancomycin and imipenem, but frequent use of
fluoroquinolones in the community or at clinics.
Diekema et al.
48
analyzed the American Hospital
Association annual survey data, and reported a
greater prevalence of oxacillin-resistant S. aureus,
vancomycin-resistant enterococci, fluoroquino-
lone-resitant E. coli, and ESBL-producing K.
pneumoniae in teaching hospitals than non-
teaching hospitals, and in > 199-bed hospitals than
smaller hospitals.
In conclusion, oxacillin-resistant staphylococci,
expanded-spectrum cephalosporin-resistant K.
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pneumoniae and fluoroquinolone-resistant E. coli,
Acinetobacter spp., and P. aeruginosa were highly
prevalent problem organisms in Korea in 2004. In-
creasing trends were observed for vancomycin-
resistant E. faecium, cefoxitin-resistant E. coli and
K. pneumoniae, and imipenem-resistant P. aeruginosa
and Acinetobacter spp. Some antimicrobial-organ-
isms combinations were also prevalent among the
commercial laboratory-tested strains.
OTHER MEMBERS OF KONSAR GROUP
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